Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS1842856 是一种特异性的Foxo1抑制剂,IC50为 30 nM。它抑制自噬,直接与 FoxO1 结合而降低 FoxO1 的活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 267 | 现货 | ||
2 mg | ¥ 376 | 现货 | ||
5 mg | ¥ 690 | 现货 | ||
10 mg | ¥ 872 | 现货 | ||
25 mg | ¥ 1,680 | 现货 | ||
50 mg | ¥ 2,970 | 现货 | ||
100 mg | ¥ 4,390 | 现货 | ||
200 mg | ¥ 6,280 | 现货 | ||
500 mg | ¥ 9,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 768 | 现货 |
产品描述 | AS1842856, a cell-permeable inhibitor, can block the transcription activity of Foxo1 (IC50: 33 nM). It can directly bind to the active Foxo1, but not the Ser256-phosphorylated form. |
靶点活性 | Foxo1:33nM |
体外活性 | AS1842856 predominantly suppresses Foxo1-mediated transactivation by directly binding to Foxo1. In HepG2 cells transiently transfected with a Foxo1 expression vector, AS1842856 potently represses Foxo1-mediated promoter activity in a dose-dependent manner similar to that seen in insulin treatment.AS1842856 administered at 0.1 μM inhibits Foxo3a- and Foxo4-mediated promoter activity by 3 and 20%, respectively. In contrast, Foxo1-mediated promoter activity is decreased by 70%. Foxo1 inhibitor AS1842856 may suppress endogenous G6Pase and PEPCK activities by decreasing their mRNA levels, which may lead to inhibition of glucose production in Fao cells[1]. |
体内活性 | Oral administration of AS1842856 to diabetic db/db mice leads to a drastic decrease in fasting plasma glucose level via the inhibition of hepatic gluconeogenic genes while administration to normal mice does not affect on the fasting plasma glucose level. Treatment with AS1842856 also suppresses an increase in plasma glucose level caused by pyruvate injection in both normal and db/db mice[1]. |
细胞实验 | Fao cells are serum-starved (1 h) and incubated for 30 min with either insulin or AS1842856 at the indicated concentration. Protein lysates are prepared from cells treated with either insulin or AS1842856, and relative concentration of phosphorylated Foxo1 protein is determined by Western blot analysis. (Only for Reference) |
分子量 | 347.38 |
分子式 | C18H22FN3O3 |
CAS No. | 836620-48-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.47 mg/mL (10 mM), Sonification is recommended
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8787 mL | 14.3935 mL | 28.7869 mL | 71.9673 mL |
5 mM | 0.5757 mL | 2.8787 mL | 5.7574 mL | 14.3935 mL | |
10 mM | 0.2879 mL | 1.4393 mL | 2.8787 mL | 7.1967 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AS1842856 836620-48-5 Apoptosis Autophagy FOXO1 AS 1842856 inhibit AS-1842856 Inhibitor inhibitor